Friday, Oct. 20, 2017|4:05 p.m.
. A brand-new, more reliable vaccine to prevent agonizing shingles has been authorized by U.S. regulators.
Drugmaker GlaxoSmithKline stated the Food and Drug Administration authorized it late Friday. It will be the 2nd vaccine for shingles, which is brought on by the chickenpox infection. Merck has actually sold a shingles vaccine for about a decade.
Studies paid for by Glaxo suggest its vaccine is more reliable, preventing shingles in about 90 percent of people. Merck’s vaccine is about HALF reliable. Both are authorized for grownups 50 years and older.
About one-third of people who have actually had chickenpox get shingles. The virus comes back years later, activating an uncomfortable rash and in some cases nerve discomfort that sticks around for months.
Glaxo said the price of Shingrix without insurance coverage will be $280 for two dosages.